Expertise in RNAi Leverage Mirimus' core strengths in RNA interference and CRISPR-based models for drug discovery to offer targeted collaboration on target validation, assay development, and model creation for prospective pharma partners.

Diagnostics and Surveillance Capitalize on Mirimus' mass testing capabilities and SalivaClear platform to propose scalable, non-invasive diagnostic solutions for institutions, employers, and healthcare networks seeking efficient surveillance and regular screening programs.

High-Volume Testing Partnerships Mirimus has a track record of large-scale PCR testing collaborations with universities and schools; propose expanded or long-term surveillance contracts, technology licensing, or managed services for academic, corporate, and government clients.

Clinical and Therapeutics Pipeline With ongoing therapeutic target discovery and RNAi-based drug development, pursue co-development, research funding, or analytics partnerships to accelerate candidate validation, preclinical studies, and translational programs.

Global Health Focus Position Mirimus as a partner for global health equity initiatives by offering affordable, scalable solutions to underserved markets, enabling joint ventures, technology transfer, and capacity-building programs in emerging regions.